Adiponectin, TNF-α and inflammatory cytokines and risk of type 2 diabetes: A systematic review and meta-analysis

Cytokine

Volumn 86, Issue , 2016, Pages 100-109

  Liu, Chenxiao ^a   Feng, Xiu ^a   Li, Qi ^a   Wang, Ying ^a   Li, Qian ^a   Hua, Majian ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Adiponectin; Cytokine; Inflammation; TNF ; Type 2 diabetes

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; GLUCOSE; INSULIN; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; CYTOKINE; IL6 PROTEIN, HUMAN; INTERLEUKIN 18 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ARTICLE; DISEASE ASSOCIATION; GLUCOSE BLOOD LEVEL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; ADULT; ANIMAL; BLOOD; DISEASE MODEL; FEMALE; IMMUNOLOGY; MALE; META ANALYSIS; MIDDLE AGED; MOUSE; STATISTICAL MODEL; YOUNG ADULT;

ADIPONECTIN; ADULT; ANIMALS; C-REACTIVE PROTEIN; CYTOKINES; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-18; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MICE; MIDDLE AGED; MODELS, STATISTICAL; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84982740442     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2016.06.028     Document Type: Article

References (52)

1. [1] Sarangi, R., Padhi, S., Mohapatra, S., Swain, S., Padhy, R.K., Mandal, M.K., Patro, S.K., Kumar, S., Serum high sensitivity C-reactive protein, nitric oxide metabolites, plasma fibrinogen, and lipid parameters in Indian type 2 diabetic males. Diabetes Metab. Synd. 6:1 (2012), 9–14.
2. [2] Calle, M.C., Fernandez, M.L., Inflammation and type 2 diabetes. Diabetes Metab. 38:3 (2012), 183–191.
3. [3] King, G.L., The role of inflammatory cytokines in diabetes and its complications. J. Periodontol. 79:Suppl. 8 (2008), 1527–1534.
4. [4] Weisberg, S.P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R.L., Ferrante, A.W. Jr., Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Investig. 112:12 (2003), 1796–1808.
5. [5] Xu, H., Barnes, G.T., Yang, Q., Tan, G., Yang, D., Chou, C.J., Sole, J., Nichols, A., Ross, J.S., Tartaglia, L.A., Chen, H., Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Investig. 112:12 (2003), 1821–1830.
6. [6] Perego, L., Pizzocri, P., Corradi, D., Maisano, F., Paganelli, M., Fiorina, P., Barbieri, M., Morabito, A., Paolisso, G., Folli, F., Pontiroli, A.E., Circulating leptin correlates with left ventricular mass in morbid (grade III) obesity before and after weight loss induced by bariatric surgery: a potential role for leptin in mediating human left ventricular hypertrophy. J. Clin. Endocrinol. Metab. 90:7 (2005), 4087–4093.
7. [7] Guha, M., Bai, W., Nadler, J.L., Natarajan, R., Molecular mechanisms of tumor necrosis factor alpha gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways. J. Biol. Chem. 275:23 (2000), 17728–17739.
8. [8] Morohoshi, M., Fujisawa, K., Uchimura, I., Numano, F., Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro. Diabetes 45:7 (1996), 954–959.
9. [9] Barzilay, J.I., Abraham, L., Heckbert, S.R., Cushman, M., Kuller, L.H., Resnick, H.E., Tracy, R.P., The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 50:10 (2001), 2384–2389.
10. [10] Freeman, D.J., Norrie, J., Caslake, M.J., Gaw, A., Ford, I., Lowe, G.D., O'Reilly, D.S., Packard, C.J., Sattar, N., West of Scotland Coronary Prevention, C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51:5 (2002), 1596–1600.
11. [11] Mirza, S., Hossain, M., Mathews, C., Martinez, P., Pino, P., Gay, J.L., Rentfro, A., McCormick, J.B., Fisher-Hoch, S.P., Type 2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin in a population of Mexican Americans: a cross-sectional study. Cytokine 57:1 (2012), 136–142.
12. [12] Bertoni, A.G., Burke, G.L., Owusu, J.A., Carnethon, M.R., Vaidya, D., Barr, R.G., Jenny, N.S., Ouyang, P., Rotter, J.I., Inflammation and the incidence of type 2 diabetes: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care 33:4 (2010), 804–810.
13. [13] Marques-Vidal, P., Schmid, R., Bochud, M., Bastardot, F., von Kanel, R., Paccaud, F., Glaus, J., Preisig, M., Waeber, G., Vollenweider, P., Adipocytokines, hepatic and inflammatory biomarkers and incidence of type 2 diabetes. The CoLaus study. PLoS ONE, 7(12), 2012, e51768.
14. [14] Yokota, T., Oritani, K., Takahashi, I., Ishikawa, J., Matsuyama, A., Ouchi, N., Kihara, S., Funahashi, T., Tenner, A.J., Tomiyama, Y., Matsuzawa, Y., Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96:5 (2000), 1723–1732.
15. [15] Ouchi, N., Kihara, S., Arita, Y., Nishida, M., Matsuyama, A., Okamoto, Y., Ishigami, M., Kuriyama, H., Kishida, K., Nishizawa, H., Hotta, K., Muraguchi, M., Ohmoto, Y., Yamashita, S., Funahashi, T., Matsuzawa, Y., Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103:8 (2001), 1057–1063.
16. [16] Lindsay, R.S., Funahashi, T., Hanson, R.L., Matsuzawa, Y., Tanaka, S., Tataranni, P.A., Knowler, W.C., Krakoff, J., Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360:9326 (2002), 57–58.
17. [17] Thorand, B., Zierer, A., Baumert, J., Meisinger, C., Herder, C., Koenig, W., Associations between leptin and the leptin/adiponectin ratio and incident Type 2 diabetes in middle-aged men and women: results from the MONICA/KORA Augsburg study 1984–2002. Diabetic Med.: J. Brit. Diabetic Assoc. 27:9 (2010), 1004–1011.
18. [18] Attar, M.J., Mohammadi, S., Karimi, M., Hosseinnezhad, A., Hosseini, S.H., Eshraghian, M.R., Jafari, N., Rahmani, M., Karimi, F., Nezhad, M.K., Association of adiponectin with dietary factors and cardiovascular risk factors in type 2 diabetes mellitus patients. Diabetes Metab. Synd. 7:1 (2013), 3–7.
19. [19] Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., Ezaki, O., Akanuma, Y., Gavrilova, O., Vinson, C., Reitman, M.L., Kagechika, H., Shudo, K., Yoda, M., Nakano, Y., Tobe, K., Nagai, R., Kimura, S., Tomita, M., Froguel, P., Kadowaki, T., The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7:8 (2001), 941–946.
20. [20] Krogh-Madsen, R., Plomgaard, P., Moller, K., Mittendorfer, B., Pedersen, B.K., Influence of TNF-alpha and IL-6 infusions on insulin sensitivity and expression of IL-18 in humans. Am. J. Physiol. Endocrinol. Metab. 291:1 (2006), E108–E114.
21. [21] Cosentino, M., Picozzi, M., The declaration of Helsinki and post-study access to effective drug treatments for subjects participating in clinical trials. Bioethics 26:7 (2012), 393–394.
22. [22] Sinclair, A.J., Task, U.K. Finish Group of Diabetes, Good clinical practice guidelines for care home residents with diabetes: an executive summary. Diabetic Med.: J. Brit. Diabetic Assoc. 28:7 (2011), 772–777.
23. [23] Zhang, M., Chen, P., Chen, S., Sun, Q., Zeng, Q.C., Chen, J.Y., Liu, Y.X., Cao, X.H., Ren, M., Wang, J.K., The association of new inflammatory markers with type 2 diabetes mellitus and macrovascular complications: a preliminary study. Eur. Rev. Med. Pharmacol. Sci. 18:11 (2014), 1567–1572.
24. [24] Hivert, M.F., Sun, Q., Shrader, P., Mantzoros, C.S., Meigs, J.B., Hu, F.B., Circulating IL-18 and the risk of type 2 diabetes in women. Diabetologia 52:10 (2009), 2101–2108.
25. [25] Negi, S.I., Pankow, J.S., Fernstrom, K., Hoogeveen, R.C., Zhu, N., Couper, D., Schmidt, M.I., Duncan, B.B., Ballantyne, C.M., Racial differences in association of elevated interleukin-18 levels with type 2 diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care 35:7 (2012), 1513–1518.
26. [26] Pradhan, A.D., Manson, J.E., Rifai, N., Buring, J.E., Ridker, P.M., C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:3 (2001), 327–334.
27. [27] Spranger, J., Kroke, A., Mohlig, M., Hoffmann, K., Bergmann, M.M., Ristow, M., Boeing, H., Pfeiffer, A.F., Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52:3 (2003), 812–817.
28. [28] Wannamethee, S.G., Lowe, G.D., Rumley, A., Cherry, L., Whincup, P.H., Sattar, N., Adipokines and risk of type 2 diabetes in older men. Diabetes Care 30:5 (2007), 1200–1205.
29. [29] Liu, S., Tinker, L., Song, Y., Rifai, N., Bonds, D.E., Cook, N.R., Heiss, G., Howard, B.V., Hotamisligil, G.S., Hu, F.B., Kuller, L.H., Manson, J.E., A prospective study of inflammatory cytokines and diabetes mellitus in a multiethnic cohort of postmenopausal women. Arch. Intern. Med. 167:15 (2007), 1676–1685.
30. [30] Ley, S.H., Harris, S.B., Connelly, P.W., Mamakeesick, M., Gittelsohn, J., Hegele, R.A., Retnakaran, R., Zinman, B., Hanley, A.J., Adipokines and incident type 2 diabetes in an Aboriginal Canadian [corrected] population: the Sandy Lake Health and Diabetes Project. Diabetes Care 31:7 (2008), 1410–1415.
31. [31] Krakoff, J., Funahashi, T., Stehouwer, C.D., Schalkwijk, C.G., Tanaka, S., Matsuzawa, Y., Kobes, S., Tataranni, P.A., Hanson, R.L., Knowler, W.C., Lindsay, R.S., Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 26:6 (2003), 1745–1751.
32. [32] Duncan, B.B., Schmidt, M.I., Pankow, J.S., Ballantyne, C.M., Couper, D., Vigo, A., Hoogeveen, R., Folsom, A.R., Heiss, G., Atherosclerosis Risk in Communities, Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 52:7 (2003), 1799–1805.
33. [33] Thorand, B., Lowel, H., Schneider, A., Kolb, H., Meisinger, C., Frohlich, M., Koenig, W., C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984–1998. Arch. Intern. Med. 163:1 (2003), 93–99.
34. [34] Hu, F.B., Meigs, J.B., Li, T.Y., Rifai, N., Manson, J.E., Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 53:3 (2004), 693–700.
35. [35] Dehghan, A., Kardys, I., de Maat, M.P., Uitterlinden, A.G., Sijbrands, E.J., Bootsma, A.H., Stijnen, T., Hofman, A., Schram, M.T., Witteman, J.C., Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes 56:3 (2007), 872–878.
36. [36] Doi, Y., Kiyohara, Y., Kubo, M., Ninomiya, T., Wakugawa, Y., Yonemoto, K., Iwase, M., Iida, M., Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: the Hisayama Study. Diabetes Care 28:10 (2005), 2497–2500.
37. [37] Laaksonen, D.E., Niskanen, L., Nyyssonen, K., Punnonen, K., Tuomainen, T.P., Valkonen, V.P., Salonen, R., Salonen, J.T., C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 47:8 (2004), 1403–1410.
38. [38] Thorand, B., Baumert, J., Kolb, H., Meisinger, C., Chambless, L., Koenig, W., Herder, C., Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 1984–2002. Diabetes Care 30:4 (2007), 854–860.
39. [39] Armijo-Olivo, S., Stiles, C.R., Hagen, N.A., Biondo, P.D., Cummings, G.G., Assessment of study quality for systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias Tool and the Effective Public Health Practice Project Quality Assessment Tool: methodological research. J. Eval. Clin. Practice 18:1 (2012), 12–18.
40. [40] Lee, C.C., Adler, A.I., Sandhu, M.S., Sharp, S.J., Forouhi, N.G., Erqou, S., Luben, R., Bingham, S., Khaw, K.T., Wareham, N.J., Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis. Diabetologia 52:6 (2009), 1040–1047.
41. [41] Han, T.S., Sattar, N., Williams, K., Gonzalez-Villalpando, C., Lean, M.E., Haffner, S.M., Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 25:11 (2002), 2016–2021.
42. [42] Feve, B., Bastard, J.P., The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat. Rev. Endocrinol. 5:6 (2009), 305–311.
43. [43] Ruan, H., Miles, P.D., Ladd, C.M., Ross, K., Golub, T.R., Olefsky, J.M., Lodish, H.F., Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-alpha: implications for insulin resistance. Diabetes 51:11 (2002), 3176–3188.
44. [44] Hotamisligil, G.S., The role of TNFalpha and TNF receptors in obesity and insulin resistance. J. Intern. Med. 245:6 (1999), 621–625.
45. [45] Hosogai, N., Fukuhara, A., Oshima, K., Miyata, Y., Tanaka, S., Segawa, K., Furukawa, S., Tochino, Y., Komuro, R., Matsuda, M., Shimomura, I., Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 56:4 (2007), 901–911.
46. [46] Garcia, C., Feve, B., Ferre, P., Halimi, S., Baizri, H., Bordier, L., Guiu, G., Dupuy, O., Bauduceau, B., Mayaudon, H., Diabetes and inflammation: fundamental aspects and clinical implications. Diabetes Metab. 36:5 (2010), 327–338.
47. [47] Li, S., Shin, H.J., Ding, E.L., van Dam, R.M., Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 302:2 (2009), 179–188.
48. [48] Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H.I., Spinas, G.A., Kaiser, N., Halban, P.A., Donath, M.Y., Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J. Clin. Investig. 110:6 (2002), 851–860.
49. [49] Donath, M.Y., Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat. Rev. Drug Discovery 13:6 (2014), 465–476.
50. [50] Dinarello, C.A., Donath, M.Y., Mandrup-Poulsen, T., Role of IL-1beta in type 2 diabetes. Curr. Opin. Endocrinol. Diabetes Obes. 17:4 (2010), 314–321.
51. [51] Thorand, B., Kolb, H., Baumert, J., Koenig, W., Chambless, L., Meisinger, C., Illig, T., Martin, S., Herder, C., Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA/KORA Augsburg Study, 1984–2002. Diabetes 54:10 (2005), 2932–2938.
52. [52] Wang, X., Bao, W., Liu, J., Ouyang, Y.Y., Wang, D., Rong, S., Xiao, X., Shan, Z.L., Zhang, Y., Yao, P., Liu, L.G., Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care 36:1 (2013), 166–175.